Breaking News

Abbott To Acquire Biologic for Pain

Abbott has entered into a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott has entered into a definitive agreement to acquire the global rights to PanGenetics BV’s PG110 fully humanized antibody to Nerve Growth Factor (NGF). The agreement includes an upfront payment of $170 million plus additional milestone payments, for a total of $190 million, as well as royalties. PG110 is a biologic in Phase I development for the treatment of chronic pain. NGF is released at sites of tissue damage and inflammation, and plays a significant role in the transmission of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters